Co-Cyprindiol is commonly used to help manage symptoms related to systemic imbalance caused by androgen sensitivity in women. This therapy is relevant for easing challenging symptoms clustered around the skin and hair.

The primary use is to address moderate to severe acne lesions and associated seborrhoea (very oily skin) that have failed to respond adequately to standard treatments, as well as pronounced symptoms of hirsutism (excessive hair growth). This systemic approach is relevant in chronic conditions like the skin and hair manifestations of Polycystic Ovary Syndrome (PCOS), where it supports the regulation of the menstrual cycle. Furthermore, the combination generally contributes to the dual benefit of providing supportive oral contraception concurrent with the hormonal symptom correction. This benefit contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.

Quick Fact: Support for Androgen-Driven Skin and Hair Symptoms

Regulatory References

1. GOV.UK Drug Safety Update

Eligibility Map: Who can and cannot use Co-Cyprindiol

Co-Cyprindiol (Cyproterone acetate/Ethinyl Estradiol) is approved for use in women of reproductive age who have reached menarche. Regulatory bodies define strict constraints on its use due to the drug’s dual hormonal composition. It is not indicated for use in pre-pubertal girls or post-menopausal women.

Absolute Contraindications

Use is strictly contraindicated for several populations, primarily due to the risk of blood clots associated with the oestrogen component. Individuals must not use this medicine if they have, or have a history of:

• Thromboembolic Events: Current or previous Venous Thromboembolism (VTE) or Arterial Thromboembolism (ATE), or known thrombophilia.
• Liver Disease/Tumours: Severe liver disease or liver tumours (benign or malignant).
• Malignancies: Known or suspected hormone-dependent malignancies, or a history of meningioma.
• Vascular Risk Factors: Severe hypertension, diabetes mellitus with vascular damage, or migraine with focal neurological symptoms.
• Pregnancy & Lactation: Use is absolutely contraindicated during pregnancy and is not recommended while breastfeeding.

Eligibility Restrictions

Treatment duration is restricted; use must be limited and stopped 3 to 4 cycles after the androgen condition is resolved. Furthermore, the medicine is contraindicated if used concurrently with any other hormonal contraceptive.

Interactions with other medicines and products

This section details officially documented interaction patterns for Co-Cyprindiol based strictly on regulatory sources.

---

Contraindicated Combinations

Co-administration with any other hormonal contraceptive is formally contraindicated. Additionally, co-use is strictly prohibited with certain Hepatitis C combination products containing ombitasvir/paritaprevir/ritonavir and dasabuvir, or glecaprevir/pibrentasvir, or sofosbuvir/velpatasvir/voxilaprevir, due to the risk of elevated liver enzyme levels (ALT).

Pharmacokinetic Interactions

Substances that are strong hepatic enzyme inducers (primarily CYP3A4) are documented to reduce the plasma concentrations of Co-Cyprindiol’s active ingredients. This includes certain anti-seizure medicines (e.g., phenytoin, carbamazepine), the antibiotic rifampicin, and the herbal product St. John’s wort. Reduced concentrations can lead to a loss of contraceptive efficacy. Conversely, strong CYP3A4 inhibitors (e.g., ketoconazole) may increase exposure to the hormonal components.

Pharmacodynamic Effects and Monitoring

Co-Cyprindiol may interfere with the action of other drugs. For instance, it can slow the removal of corticosteroids (such as prednisolone), potentially increasing their serum concentration. It also requires monitoring when co-administered with oral anticoagulants (e.g., warfarin), as their effect may be altered. Conditions causing severe malabsorption, like vomiting or diarrhea, are documented to reduce the contraceptive effectiveness of the oral tablet.

The mechanism of Co-Cyprindiol, a combination of Cyproterone acetate (CPA) and Ethinyl Estradiol (EE), is defined by three coordinated pharmacodynamic actions.

Peripheral Androgen Receptor Blockade

The anti-androgen component, CPA, acts as a competitive antagonist at the Androgen Receptor (AR), particularly in androgen-sensitive cells of the skin. By physically blocking the AR, CPA prevents endogenous androgens from binding and initiating excessive cell proliferation and secretion processes. This mechanism directly contributes to reducing the proliferative and secretory activity of androgen-sensitive tissues.

Central HPO Axis Suppression

Both the estrogen and progestogen components exert constant negative feedback on the Hypothalamus-Pituitary-Ovarian (HPO) Axis. This action inhibits the pulsatile release of LH and FSH, stabilizing hormone levels and preventing the mid-cycle surge necessary for ovulation. This mechanism is primary for the inhibition of ovulation and reducing the ovarian output of endogenous androgens.

Systemic Free Androgen Sequestration

The EE component induces the liver to synthesize and release high levels of Sex Hormone-Binding Globulin (SHBG). This protein binds tightly to androgens in the bloodstream, chemically sequestering them and causing a profound reduction in the concentration of free testosterone available to activate peripheral receptors. This systemic action complements the receptor blockade, resulting in a coordinated effect on androgen activity.

Co-Cyprindiol is administered exclusively via the oral route as a fixed-dose tablet, containing 2 mg of cyproterone acetate and 0.035 mg of ethinyl estradiol. The standard administration regimen requires taking one tablet daily to provide systemic hormonal modulation.

The usage is structured around a defined cyclic schedule, consisting of 21 consecutive days of active tablet-taking, followed by a mandatory 7-day tablet-free interval. Each subsequent 21-day course commences on the day immediately following the break. For proper establishment of the regimen, consistent daily timing is required, and the initial course should typically begin on the first day of the menstrual cycle. The tablet should be taken with some liquid.

The overall duration of use is defined by the clinical response. Treatment is typically necessary for at least three months before the effects can be fully assessed. Administration is recommended to be discontinued 3 to 4 cycles after the condition being addressed has completely resolved. The necessity for continued administration must be subject to periodic re-evaluation.

This medicine is designated for use in women of reproductive age. A key procedural rule is the strict prohibition of concurrent use with any other hormonal contraceptive. Furthermore, if the intake of a tablet is delayed by more than 12 hours, the contraceptive element of the medicine may be compromised.

Research Evidence / Overview of Studies for Co-Cyprindiol

---

Evidence for Use in Moderate to Severe Acne and Seborrhoea

Research exploring how Co-Cyprindiol was studied for the treatment of moderate to severe acne and associated very oily skin (seborrhoea) has been documented in numerous sources. The evidence base includes Randomized Controlled Trials (RCTs) and general clinical studies. Research was applied in contexts involving women of reproductive age whose acne was often severe or had been refractory (unresponsive) to standard treatments.

In these trials, researchers primarily monitored changes in acne severity using standardized rating scales and evaluated outcomes related to scarring. Studies monitored symptom patterns over defined time intervals, typically requiring a minimum of three to six months to assess relevant clinical changes in the skin. Certainty remains low for evidence specifically describing the Polycystic Ovary Syndrome (PCOS) subgroup, and there is limited information for how outcomes are maintained consistently over the long term.

---

Evidence for Use in Pronounced Hirsutism (Excessive Hair Growth)

Evidence was evaluated in women with pronounced hirsutism (excessive unwanted hair growth). The research includes RCTs and systematic reviews, which examined women of reproductive age. Studies monitored outcomes using validated scoring systems, such as the Ferriman-Gallwey Score, and also examined changes in endocrine parameters. Studies observed responses over observation periods extending up to 24 months.

Evidence on Contraceptive Action and Cycle Regulation

Co-Cyprindiol was studied for its dual role, with research examining outcomes related to contraception. The evidence structure is supported by large-scale observational studies and general epidemiological data. Research examined outcomes related to the prevention of pregnancy, alongside monitoring outcomes related to menstrual cycle regularity. Data are still emerging, and limitations persist in observational studies regarding the understanding of metabolic and cardiovascular profiles.

---

What Remains Uncertain in the Research Landscape

Follow-up durations were limited in many efficacy trials, meaning that long-term effects are not fully established. A consistent limitation noted is that sample sizes were modest in some trials, which may limit the certainty of certain findings. For specific areas, such as the differential outcomes based on varying doses of the anti-androgen component, comparative evidence is lacking, and certainty remains low.

Key Studies & References

1. Cyproterone acetate/ethinylestradiol: balance of benefits and risks remains positive, but reminders of risk minimisation measures, including venous thromboembolism risk
2. Evidence summary: Cyproterone acetate/ethinylestradiol (Dianette) for acne

Common questions about Co-Cyprindiol (FAQ)

---

Q: How quickly does Co-Cyprindiol start to work for skin issues?

A: Official guidelines state that treatment must be continued for at least three months before a healthcare professional can fully assess the effects on androgen-related skin conditions. Treatment guidance emphasizes the need to continue the prescribed course to allow for full assessment.

Q: Is Co-Cyprindiol a long-term treatment or is it usually temporary?

A: Co-Cyprindiol is generally described as a temporary use medicine. According to regulatory safety updates, treatment is recommended to be discontinued three to four cycles after the condition being treated (such as acne or hirsutism) has completely resolved.

Q: Can men use Co-Cyprindiol for any conditions?

A: No. Regulatory documents state that this medicine is strictly indicated only for use in women of reproductive age who have reached menarche (the start of menstruation).

Q: What is the difference between Co-Cyprindiol and other hormonal treatments for acne?

A: Official classification states Co-Cyprindiol is a combination medicine containing an anti-androgen and an estrogen component. Its dual action addresses hormone regulation while also providing contraception. Regulatory guidance suggests it is typically reserved for use only after other standard acne treatments have not been successful.

Q: Does Co-Cyprindiol interact with antibiotics?

A: The official product information specifically documents an interaction with the antibiotic rifampicin, which is a strong enzyme inducer, potentially reducing the effectiveness of Co-Cyprindiol. Official product information notes that additional contraceptive precautions may be needed if certain interacting medicines are taken.

Q: Are there any herbal supplements that interfere with Co-Cyprindiol?

A: Yes, the herbal product St. John’s wort (Hypericum perforatum) is specifically documented in official sources to interfere with the medicine. It can reduce the amount of Co-Cyprindiol’s active ingredients in the bloodstream, which may lead to a loss of contraceptive effectiveness.

Q: Can Co-Cyprindiol be used by women over 35?

A: The medicine is generally indicated for women of reproductive age. However, regulatory warnings specify that the risk of serious blood clots (thromboembolism) is further increased in women who smoke, particularly those over the age of 35.

Q: Is Co-Cyprindiol used for hirsutism (excessive hair growth)?

A: Yes, Co-Cyprindiol is officially indicated for the treatment of moderate to severe hirsutism (excessive unwanted hair growth) in women of reproductive age, where the condition is linked to male hormone overactivity.

Q: What happens if I stop taking Co-Cyprindiol suddenly?

A: The official product information does not detail the effects of sudden discontinuation. It advises that use should be stopped three to four cycles after the condition has resolved, which suggests a planned, controlled discontinuation when the treatment goal is met.

Q: Do you need a special prescription for Co-Cyprindiol compared to a regular birth control pill?

A: Co-Cyprindiol is classified as a prescription-only medicine (POM). Regulatory bodies restrict its use, advising that it should not be prescribed solely for contraception and is generally reserved for androgen-related conditions that have not responded to other treatments.

Q: Does Co-Cyprindiol affect mood or cause depression?

A: Changes in mood, including a depressed mood, are listed in the official documents as a common side effect, meaning they may affect up to 1 in 10 users. If persistent changes in mood are observed, consultation with a healthcare professional is consistent with patient safety guidance.

Q: Do any official medical bodies recommend Co-Cyprindiol as a first-line treatment?

A: Official guidance states that for the treatment of acne, this medicine should only be used after topical therapy or systemic antibiotic treatment has failed. This regulatory stipulation indicates that it is generally not classified as a first-line therapy.

Q: Can Co-Cyprindiol be used to treat hair loss?

A: Official therapeutic indications primarily focus on acne and hirsutism. However, the medicine's anti-androgen component has been studied for use in conditions such as androgenic alopecia (female-pattern hair loss), which is also related to male hormone overactivity.

Q: Are there generic versions of Co-Cyprindiol?

A: Yes, Co-Cyprindiol is the generic non-proprietary name for the specific fixed-dose formulation. Proprietary equivalents containing the exact same active ingredients and dosage are known by various brand names, such as Dianette and Diane-35.

Q: Does Co-Cyprindiol make the skin more sensitive to the sun?

A: The official list of documented side effects does not explicitly list photosensitivity (sun sensitivity). However, skin reactions such as rash or urticaria are listed as uncommon side effects.

Q: Is it safe to use Co-Cyprindiol before or after surgery?

A: Regulatory documents note that major surgery and any prolonged immobilization are documented risk factors for serious blood clots (VTE). Healthcare providers consider stopping hormonal contraceptives well in advance of a planned surgical procedure or a period of prolonged immobilization.

Q: Is Co-Cyprindiol known by different brand names internationally?

A: Yes, the fixed-dose formulation of cyproterone acetate and ethinyl estradiol is marketed under different brand names internationally, including Dianette and Diane-35.

Q: Can Co-Cyprindiol cause changes in vision or eye problems?

A: Official warnings related to the use of cyproterone acetate advise that symptoms of a rare type of tumor (meningioma) can include changes in vision, along with other neurological symptoms like hearing loss or ringing in the ears.

Q: Are there any age limits for who can use Co-Cyprindiol?

A: The medicine is indicated for women of reproductive age who have reached menarche. It is not indicated for use in pre-pubertal girls or post-menopausal women. The risk profile also increases for women over 35 who smoke.

Q: Is Co-Cyprindiol effective for reducing oiliness of the skin and hair?

A: Yes, Co-Cyprindiol is officially indicated for the treatment of moderate to severe acne associated with very oily skin (seborrhoea). This anti-androgen effect works to reduce the excess oil production of the skin.

Q: Are there specific official guidelines for prescribing Co-Cyprindiol?

A: Yes, official safety guidelines from regulatory bodies specify that the medicine should only be used after other standard treatments have failed and that its use should be limited to 3–4 cycles after the condition has been resolved.

Q: Is the primary action of Co-Cyprindiol to regulate hormones?

A: The overall purpose of the medicine is to provide a systemic treatment that addresses conditions linked to the overactivity of male hormones, or androgens, in women. This is achieved through a combined hormonal action that blocks androgen effects and regulates hormone production.

Q: What happens if I miss a dose of Co-Cyprindiol by less than 12 hours?

A: Official administration guidelines typically state that if a tablet is missed by less than 12 hours, it should be taken immediately. In this specific scenario, the contraceptive protection is generally maintained.

Q: Does Co-Cyprindiol cause weight gain, or is it fluid retention?

A: Official product information lists 'weight increase' as a common side effect, which means it may affect up to 1 in 10 users. Separately, 'fluid retention' is listed as an uncommon side effect. The exact underlying cause is not detailed in the general patient information.

Q: What research evidence supports the use of Co-Cyprindiol for PCOS symptoms?

A: Clinical reviews have examined Co-Cyprindiol for its use in treating symptoms often associated with Polycystic Ovary Syndrome (PCOS), such as hirsutism and acne. Evidence indicates effectiveness in improving menstrual regularity compared to some other treatments for these symptoms.

Q: Is the blood clot risk the same for all women taking Co-Cyprindiol?

A: No. Official documents specify that the excess risk of blood clots is highest during the first year of use or upon restarting the medicine after a long break. The risk is also increased by other documented factors such as age, smoking, and a family history of thrombosis.

Q: Can I take Co-Cyprindiol if I have a history of migraines?

A: Use is strictly contraindicated (forbidden) in individuals with a history of migraine with focal neurological symptoms (migraines accompanied by temporary loss of vision or other sensory disturbances). The product information states the contraindication applies specifically to migraine with focal neurological symptoms.

Q: Can Co-Cyprindiol be taken while breastfeeding?

A: Use is absolutely contraindicated during pregnancy and is not recommended while breastfeeding. Regulatory information states that the hormonal components may reduce the quantity and quality of breast milk.

Q: Does Co-Cyprindiol affect fertility in the future?

A: Regulatory overviews of hormonal contraceptives generally indicate that the medicine is designed to be fully reversible. Fertility typically returns after a woman discontinues use, and the medicine does not have a known lasting negative impact on a woman's ability to conceive.

How to Store and Dispose of Co-Cyprindiol?

Co-Cyprindiol tablets require specific storage conditions to maintain the stability of the active ingredients.

---

Official Storage Requirements

Requirement	Condition
Maximum Temperature	Store below 25 C
Protection Rule	Protect from light and moisture
Container Rule	Keep in the original blister pack and outer carton
Child Safety	Keep out of the sight and reach of children

Storage outside of the original packaging or above the stated temperature may compromise the medicine's integrity.

---

Disposal Instructions

Disposal must adhere to environmental protection guidelines. Unused or expired Co-Cyprindiol must not be thrown away with household waste or disposed of via wastewater (flushed down the toilet or sink). The product should be returned to a pharmacy or designated collection point to be disposed of according to local requirements.